Pyxis Oncology (PYXS) EBT Margin (2024 - 2025)
Pyxis Oncology's (PYXS) quarterly EBT Margin came in at 154.04% in Q4 2025, up 75.96% quarter-over-quarter from 640.82% in Q2 2025.
Powered by 
Analysis
Pyxis Oncology (PYXS) EBT Margin (2024 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported EBT Margin for 2 consecutive years, with 154.04% the latest figure, recorded in Q4 2025.
- On a quarterly basis, EBT Margin changed N/A year-over-year to 154.04% in Q4 2025; TTM through Jun 2026 was 594.77%, a 290459.0% increase from a year earlier, with the FY2025 full-year figure at 564.55%, down 7220.0% from the prior year.
- EBT Margin was 154.04% for Q4 2025 at Pyxis Oncology, up from 640.82% in the prior quarter.
- Over five years, EBT Margin peaked at 24.8% in Q1 2024 and troughed at 640.82% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,427.46% |
| 10 | Pyxis Oncology | 208.61 Mn | 175.62 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -154.04% |
| Jun 30, 2025 | -640.82% |
| Mar 31, 2024 | -24.80% |